Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Usana Health Sciences (USNA) over the last 15 years, with Q3 2025 value amounting to $102.4 million.

  • Usana Health Sciences' Other Accumulated Expenses fell 491.28% to $102.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.4 million, marking a year-over-year decrease of 491.28%. This contributed to the annual value of $104.6 million for FY2024, which is 310.03% down from last year.
  • Usana Health Sciences' Other Accumulated Expenses amounted to $102.4 million in Q3 2025, which was down 491.28% from $103.7 million recorded in Q2 2025.
  • In the past 5 years, Usana Health Sciences' Other Accumulated Expenses ranged from a high of $149.9 million in Q1 2021 and a low of $97.2 million during Q2 2024
  • Moreover, its 5-year median value for Other Accumulated Expenses was $111.7 million (2022), whereas its average is $119.2 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 2380.19% in 2021, then crashed by 1994.62% in 2022.
  • Usana Health Sciences' Other Accumulated Expenses (Quarter) stood at $144.3 million in 2021, then decreased by 7.95% to $132.8 million in 2022, then dropped by 18.67% to $108.0 million in 2023, then fell by 3.1% to $104.6 million in 2024, then decreased by 2.1% to $102.4 million in 2025.
  • Its Other Accumulated Expenses stands at $102.4 million for Q3 2025, versus $103.7 million for Q2 2025 and $100.4 million for Q1 2025.